Aviragen Therapeutics Inc (AVIR) Shares Up 7.5%

Aviragen Therapeutics Inc (NASDAQ:AVIR) shot up 7.5% on Tuesday . The company traded as high as $0.62 and last traded at $0.57. 1,388,500 shares were traded during trading, an increase of 281% from the average session volume of 364,497 shares. The stock had previously closed at $0.53.

Separately, HC Wainwright restated a “hold” rating on shares of Aviragen Therapeutics in a research report on Monday, November 6th.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.63 and a current ratio of 6.63.

An institutional investor recently bought a new position in Aviragen Therapeutics stock. Virtu KCG Holdings LLC bought a new position in shares of Aviragen Therapeutics Inc (NASDAQ:AVIR) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 222,934 shares of the biotechnology company’s stock, valued at approximately $149,000. Virtu KCG Holdings LLC owned about 0.58% of Aviragen Therapeutics as of its most recent SEC filing. Institutional investors own 24.20% of the company’s stock.

WARNING: “Aviragen Therapeutics Inc (AVIR) Shares Up 7.5%” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/11/14/aviragen-therapeutics-inc-avir-shares-up-7-5.html.

Aviragen Therapeutics Company Profile

Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.

Receive News & Ratings for Aviragen Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviragen Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply